Understanding Malignancy Risks With the Use of CAR T-cell Therapies
Miguel-Angel Perales, MD, shares background on the unique design of a real-world analysis of liso-cel in LBCL in which he and his co-investigators prospectively collected retrospective data.
EP: 1.The Expanding Utility of CAR T-Cell Therapy in LBCL
EP: 2.Sequencing With CAR T-Cell Therapy for LBCL
EP: 3.CAR T-Cell Therapy as a Second-Line Treatment for LBCL
Now Viewing
EP: 4.Understanding Malignancy Risks With the Use of CAR T-cell Therapies
EP: 5.Real World Findings for Liso-Cel in LBCL From the Cell Therapy Consortium
EP: 6.Expert Perspective on Real-World Follow-Up Analyses of Liso-Cel in LBCL
EP: 7.Bridging Therapy With CAR T-Cell Therapy in LBCL
EP: 8.The Impact of Real-World Analyses in the Utilization of CAR T-Cell Therapy in LBCL
Related Videos
Related Content
The CAR-T Versus Bispecific Antibody Debate in Third Line LBCL
April 26th 2024Article
Emilie Aschenbrenner, PharmD, BCOP, a hematology coordinator for pharmacy at Froedtert and the Medical College of Wisconsin, discussed the advantages of each of the 2 modalities in the third and second line settings.
